Multiple Rare Disease Advocacy Groups Rank Horizon Therapeutics First in Corporate Reputation

Published on: 

Results based on a 2022 global PatientView survey.

Horizon Therapeutics plc revealed its ranking of first in overall corporate reputation among rare disease patient groups around the world who were familiar with the company. According to PatientView’s 2022 global Corporate Reputation of Pharma survey, Horizon ranked first in 10 of 14 indicators including patient centricity, patient information, integrity, access to medicines, relationships, and services. The survey included 426 patient groups who analyzed 34 pharma and biotech organizations.


“We are honored by the feedback that rare disease patient advocacy groups provided within the PatientView report,” said Matt Flesch, VP, patient advocacy, product communications, Horizon. “Our approach to patient advocacy is to participate, listen and learn, knowing that rare disease patient groups are usually the main catalyst for progress, driving awareness and education, building community, and advancing research toward treatments and cures. From the programs that we support to the initiatives that we create; our belief is that meaningful and appropriate collaboration with patient advocacy groups is core to all our work at Horizon.”

Reference: Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups. BusinessWire. August 23, 2023. Accessed August 24, 2023.